Abera Bioscience AB (FRA:8WK)

Market Cap	16.84M +57.4%
Revenue (ttm)	1.08M -25.8%
Net Income	-1.48M
EPS	-0.07
Shares Out	n/a
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	n/a
Open	0.7720
Previous Close	0.6880
Day's Range	0.7480 - 0.7720
52-Week Range	0.4440 - 0.8350
Beta	n/a
Analysts	n/a
Price Target	n/a
Earnings Date	Aug 19, 2026

About Abera Bioscience AB

Abera Bioscience AB, a platform and vaccine development company, research, design, and develops vaccines and immunotherapies based on its proprietary vaccine delivery platform in Sweden and internationally. The company’s development platform named BERA, uses for the display of antigens at the surface of outer membrane vesicles derived from genetically optimized gram-negative bacteria. Its lead vaccine candidate is a universal pneumococcal vaccine based on the platform BERA. The company also develops projects in immuno-oncology, Chlamydia, ETEC,...

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 2012
• Employees: 6
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: 8WK

Financial Performance

In 2025, Abera Bioscience AB's revenue was 11.85 million, a decrease of -18.99% compared to the previous year's 14.63 million. Losses were -10.45 million, 850.3% more than in 2024.

Financial numbers in SEK

Data Sources: S&P Global Market Intelligence and Twelve Data

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Twelve Data.

Last checked:

Jun 26, 2026

Data Sources Report a data error